ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "hyperuricemia and renal disease"

  • Abstract Number: 333 • 2019 ACR/ARP Annual Meeting

    Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients

    Justin Li1, David Yin 1, Zheng Wang 1, Mark Brigham 1, Brian LaMoreaux 2, Jeffrey Kent 2, Megan Francis-Sedlak 2, Richard Johnson 3, Nandini Hadker 1 and Gavin Miyasato 1, 1Trinity Partners, Waltham, MA, 2Horizon Therapeutics plc, Lake Forest, IL, 3University of Colorado Denver, Aurora, CO

    Background/Purpose: Although gout has been shown to be associated with poor renal outcomes among chronic kidney disease populations, this relationship is not well understood among…
  • Abstract Number: 912 • 2016 ACR/ARHP Annual Meeting

    Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease

    Gerald D. Levy1,2, Craig Cheetham3, Nazia Rashid4 and Jiaxiao Shi3, 1Internal Medicine/Rheumatology, Southern California Kaiser Permanente, Downey, CA, 2Rheumatology, Kaiser Permanente Southern California, Downey, CA, 3Research and Evaluation, Southern California Medical Group, Pasadena, CA, 4Pharmacy Analytic Services, Kaiser Permanente, Downey, CA

    Urate Lowering Therapy in Moderate to Severe Chronic Kidney Disease Levy G, Cheetham C, Shi J, Rashid N Background/Purpose:   To determine if urate lowering…
  • Abstract Number: 2349 • 2015 ACR/ARHP Annual Meeting

    The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with Severe Renal Impairment

    Ji Seon Oh and Seungwon Choi, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea

    Background/Purpose:  Febuxostat has shown to be effective and safe in the treatment of hyperuricemia in patients with mild-to-moderate renal impairment without dose adjustment. However, there…
  • Abstract Number: 232 • 2015 ACR/ARHP Annual Meeting

    Hyperuricemia, Urate Lowering Therapy and Kidney Function: A Systemic Review and Meta-Analysis

    Gaurav Sharma1, Abhishek Dubey1 and Jasvinder A. Singh2, 1Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: To determine whether hyperuricemia is associated with deterioration of kidney function and to examine whether urate-lowering therapies (ULTs) can improve or maintain kidney function.…
  • Abstract Number: 153 • 2012 ACR/ARHP Annual Meeting

    Prevention of Recurrent Calcium Stones in Subjects with Hyperuricosuria: A Randomized Controlled Trial of Febuxostat Vs Allopurinol

    David S. Goldfarb1, Patricia A. MacDonald2, Lhanoo Gunawardhana3, Solomon Chefo3 and Lachy McLean4, 1New York Universtiy Langone Medical Center, New York, NY, 2Takeda Pharmaceuticals USA, Inc., Deerfield, IL, 3Takeda Global Research & Development Center, Inc., Deerfield, IL, 4Takeda Global Research & Development Center, Inc, Deerfield, IL

    Background/Purpose:  About one-third of patients with recurrent calcium oxalate (CaOx) stones have hyperuricosuria as a urinary risk factor. Febuxostat (FEB), a newer xanthine oxidase inhibitor…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences